TME Pharma N.V. (ALTME.PA)
EUR 0.06
(-1.86%)
EUR 0.06
(-1.86%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -127 Thousand EUR | -38.04% |
| 2022 | -92 Thousand EUR | -39.46% |
| 2021 | -65.96 Thousand EUR | -4.77% |
| 2020 | -62.96 Thousand EUR | 93.88% |
| 2019 | -1.02 Million EUR | -4.77% |
| 2018 | -982 Thousand EUR | -35.45% |
| 2017 | -725 Thousand EUR | 47.31% |
| 2016 | -1.37 Million EUR | 47.06% |
| 2015 | -2.59 Million EUR | 28.85% |
| 2014 | -3.65 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -66 Thousand EUR | 0.0% |
| 2023 Q4 | 8500.00 EUR | 0.0% |
| 2023 FY | -127 Thousand EUR | -38.04% |
| 2023 Q1 | - EUR | 100.0% |
| 2023 Q2 | - EUR | 0.0% |
| 2023 Q3 | 8500.00 EUR | 0.0% |
| 2022 Q3 | - EUR | 100.0% |
| 2022 Q2 | -30 Thousand EUR | 0.0% |
| 2022 FY | -92 Thousand EUR | -39.46% |
| 2022 Q1 | - EUR | 100.0% |
| 2022 Q4 | -62 Thousand EUR | 0.0% |
| 2021 Q3 | 16.5 Thousand EUR | 148.53% |
| 2021 Q2 | -34 Thousand EUR | 0.0% |
| 2021 FY | -65.96 Thousand EUR | -4.77% |
| 2021 Q1 | - EUR | 100.0% |
| 2021 Q4 | -15.5 Thousand EUR | -193.94% |
| 2020 Q3 | 17.5 Thousand EUR | 158.33% |
| 2020 FY | -62.96 Thousand EUR | 93.88% |
| 2020 Q4 | -15.5 Thousand EUR | -188.57% |
| 2020 Q1 | - EUR | 100.0% |
| 2020 Q2 | -30 Thousand EUR | 0.0% |
| 2019 FY | -1.02 Million EUR | -4.77% |
| 2019 Q4 | -94 Thousand EUR | -56.67% |
| 2019 Q3 | -60 Thousand EUR | -148.39% |
| 2019 Q2 | 124 Thousand EUR | -9.49% |
| 2019 Q1 | 137 Thousand EUR | 0.0% |
| 2018 Q3 | - EUR | 0.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2018 FY | -982 Thousand EUR | -35.45% |
| 2017 Q3 | 117 Thousand EUR | 0.0% |
| 2017 Q1 | - EUR | -100.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 Q4 | 117 Thousand EUR | 0.0% |
| 2017 FY | -725 Thousand EUR | 47.31% |
| 2016 Q1 | 79.5 Thousand EUR | 250.0% |
| 2016 FY | -1.37 Million EUR | 47.06% |
| 2016 Q4 | 79 Thousand EUR | 0.0% |
| 2016 Q2 | 79.5 Thousand EUR | 0.0% |
| 2016 Q3 | 79 Thousand EUR | -0.63% |
| 2015 Q1 | -29.5 Thousand EUR | 0.0% |
| 2015 Q3 | -53 Thousand EUR | -79.66% |
| 2015 FY | -2.59 Million EUR | 28.85% |
| 2015 Q4 | -53 Thousand EUR | 0.0% |
| 2015 Q2 | -29.5 Thousand EUR | 0.0% |
| 2014 FY | -3.65 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 120.55% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 103.245% |
| Adocia SA | 1.38 Million EUR | 109.17% |
| Aelis Farma SA | 12.35 Million EUR | 101.028% |
| Biophytis S.A. | -803 Thousand EUR | 84.184% |
| Advicenne S.A. | 1.42 Million EUR | 108.906% |
| genOway Société anonyme | 20.1 Million EUR | 100.632% |
| IntegraGen SA | 5.01 Million EUR | 102.531% |
| Medesis Pharma S.A. | -2.66 Million EUR | 95.234% |
| Neovacs S.A. | 29.31 Thousand EUR | 533.24% |
| NFL Biosciences SA | -56.06 Thousand EUR | -126.527% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 105.899% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 91.052% |
| Sensorion SA | 3.78 Million EUR | 103.353% |
| Theranexus Société Anonyme | -4.63 Million EUR | 97.262% |
| Valbiotis SA | 2.66 Million EUR | 104.76% |
| TheraVet SA | -530.79 Thousand EUR | 76.074% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 110.024% |
| DBV Technologies S.A. | 4.15 Million EUR | 103.053% |
| Genfit S.A. | 28.22 Million EUR | 100.45% |
| GeNeuro SA | -293.8 Thousand EUR | 56.773% |
| Innate Pharma S.A. | -4.12 Million EUR | 96.918% |
| Inventiva S.A. | 17.5 Million EUR | 100.726% |
| MaaT Pharma SA | 1.65 Million EUR | 107.674% |
| MedinCell S.A. | 9.28 Million EUR | 101.367% |
| Nanobiotix S.A. | 36.2 Million EUR | 100.351% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 105.703% |
| Poxel S.A. | 1000.00 EUR | 12800.0% |
| GenSight Biologics S.A. | 3 Million EUR | 104.233% |
| Transgene SA | -28.4 Million EUR | 99.553% |
| Valneva SE | 52.83 Million EUR | 100.24% |